The present study was designed to test the hypothesis that inhibition of CPM with Mergetpa also named Plummer's inhibitor (Plummer and Ryan, 1981; Charest-Morin et al., 2014) is a valid strategy to prevent the biosynthesis of B1R agonists and thereby may offer the same therapeutic effect to B1R antagonists in insulin resistance. Here, BDKRB1 is linked to Insulin resistance.